William R. Otto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
William R. Otto has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Lara Danziger-Isakov
Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio
8 shared publications Lara Danziger-Isakov
Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, USA
4 shared publications- Brian T. Fisher
Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA
3 shared publications Grant Paulsen
Division of Infectious Diseases Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA
3 shared publications- Hilary Miller-Handley
Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center , Cincinnati, OH
3 shared publications - Adriana E. Kajon
Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA
2 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (7) , e70384
Live Attenuated Influenza Vaccine in Pediatric Liver Transplant Recipients: A Retrospective Series
Background: Influenza remains a significant cause of morbidity and mortality in pediatric patients, particularly among solid organ transplant (SOT) recipients. Live attenuated influenza vaccines (LAIV) historically have been contraindicated in SOT recipients, with very limited data on the safety of administration after SOT. Methods: We report on the general safety outcomes of a series of four pediatric liver transplant recipients who received LAIV as a part of clinical care between 2019 and 2025 due to prior severe local reaction to the inactivated influenza vaccine (IIV). All patients met specific eligibility criteria for LAIV. Electronic medical records were reviewed. Results: Among 15 administered doses, there were no serious adverse events and only three reports of mild symptoms within the 30 days following vaccination that could not be definitively attributed to LAIV. There were four confirmed influenza infections across two patients that occurred 45 days or more postvaccination; these were mild and did not require emergency department visits or hospitalization. Conclusions: In this cohort of four pediatric liver transplant recipients with severe localized side effects after IIV, LAIV was well‐tolerated without significant safety events, which suggests that safety and immunogenicity of LAIV should be further explored in transplant recipients.
- 26 June 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (7) , e70384
Open AccessLive Attenuated Influenza Vaccine in Pediatric Liver Transplant Recipients: A Retrospective Series
Background: Influenza remains a significant cause of morbidity and mortality in pediatric patients, particularly among solid organ transplant (SOT) recipients. Live attenuated influenza vaccines (LAIV) historically have been contraindicated in SOT recipients, with very limited data on the safety of administration after SOT. Methods: We report on the general safety outcomes of a series of four pediatric liver transplant recipients who received LAIV as a part of clinical care between 2019 and 2025 due to prior severe local reaction to the inactivated influenza vaccine (IIV). All patients met specific eligibility criteria for LAIV. Electronic medical records were reviewed. Results: Among 15 administered doses, there were no serious adverse events and only three reports of mild symptoms within the 30 days following vaccination that could not be definitively attributed to LAIV. There were four confirmed influenza infections across two patients that occurred 45 days or more postvaccination; these were mild and did not require emergency department visits or hospitalization. Conclusions: In this cohort of four pediatric liver transplant recipients with severe localized side effects after IIV, LAIV was well‐tolerated without significant safety events, which suggests that safety and immunogenicity of LAIV should be further explored in transplant recipients.
- Open Access
- 20 June 2026
- Vol. 13 (7)
Secondary Oral Vancomycin Prophylaxis and Clostridioides difficile Infection in Children and Young Adults With Cancer: A Retrospective Cohort Study
Secondary oral vancomycin prophylaxis has been reported to reduce rates of recurrent Clostridioides difficile infection (CDI) in adult patients, but there are limited data in pediatrics. This study sought to assess the impact of secondary oral vancomycin prophylaxis (OVP) during broad-spectrum antibiotic administration in reducing CDI in children and young adults with cancer. This was a retrospective study of children and young adults with cancer with primary CDI episode treated from 2017 to 2024. To determine the causal impact of secondary oral vancomycin prophylaxis during antibiotic administration to prevent CDI in the 6 months after the primary episode, propensity score matching and weighted generalized estimating equations were performed. The initial cohort included 163 patients who experienced primary CDI. After exclusions, 72 patients received 150 courses of broad-spectrum antibiotics within 6 months following their initial infection. Fifteen patients received 27 episodes of OVP. CDIs were not significantly decreased, occurring in 22 of 123 (17.9%) courses in patients who did not receive OVP and 2 of 27 (7.4%) in courses with prophylaxis. Propensity score matching resulted in 49 broad-spectrum antibiotic episodes from 19 patients, forming 11 matched sets. Receipt of OVP was significantly associated with reduced risk of CDI (adjusted odds ratio, 0.074 [95% confidence interval, .01–.54]). In this single-center retrospective study of children and young adults with cancer with primary CDI, receipt of OVP was significantly associated with reduced risk of CDI recurrence when receiving broad-spectrum antibiotic therapy. Given the small sample size and likely residual confounding, these findings should be considered hypothesis-generating pending confirmation in larger studies.
- 20 June 2026
- Vol. 13 (7)
Open AccessSecondary Oral Vancomycin Prophylaxis and Clostridioides difficile Infection in Children and Young Adults With Cancer: A Retrospective Cohort Study
Secondary oral vancomycin prophylaxis has been reported to reduce rates of recurrent Clostridioides difficile infection (CDI) in adult patients, but there are limited data in pediatrics. This study sought to assess the impact of secondary oral vancomycin prophylaxis (OVP) during broad-spectrum antibiotic administration in reducing CDI in children and young adults with cancer. This was a retrospective study of children and young adults with cancer with primary CDI episode treated from 2017 to 2024. To determine the causal impact of secondary oral vancomycin prophylaxis during antibiotic administration to prevent CDI in the 6 months after the primary episode, propensity score matching and weighted generalized estimating equations were performed. The initial cohort included 163 patients who experienced primary CDI. After exclusions, 72 patients received 150 courses of broad-spectrum antibiotics within 6 months following their initial infection. Fifteen patients received 27 episodes of OVP. CDIs were not significantly decreased, occurring in 22 of 123 (17.9%) courses in patients who did not receive OVP and 2 of 27 (7.4%) in courses with prophylaxis. Propensity score matching resulted in 49 broad-spectrum antibiotic episodes from 19 patients, forming 11 matched sets. Receipt of OVP was significantly associated with reduced risk of CDI (adjusted odds ratio, 0.074 [95% confidence interval, .01–.54]). In this single-center retrospective study of children and young adults with cancer with primary CDI, receipt of OVP was significantly associated with reduced risk of CDI recurrence when receiving broad-spectrum antibiotic therapy. Given the small sample size and likely residual confounding, these findings should be considered hypothesis-generating pending confirmation in larger studies.
- Open Access
A Pediatric Case of Rapidly Progressing Disseminated Human Adenovirus C1 Infection with Multiorgan Failure and Evidence of Intra-Host Variation
A strain of human adenovirus type C1 was isolated from multiple anatomical compartments in a pediatric patient with late-onset Pompe disease. Over a period of 23 days from the appearance of fever and respiratory symptoms until death, disease progression was rapid with severe disseminated disease and complications that included respiratory distress, liver failure, cardiac dysfunction, and hemophagocytic lymphohistiocytosis. Detected viral DNAemia peaked at log10 9.52 copies/mL on the last hospitalization day. Next-generation whole-genome sequencing with depth > 2700 reads/position identified the virus as closely related to the prototype strain Adenoid 71 isolated in the US in 1953, and to strains circulating worldwide in recent years. Sequence data analysis revealed the presence of intra-host single nucleotide variants (iSNV) at low frequency in the isolates recovered from a nasopharyngeal swab, blood, urine, and stool specimens obtained during the last three days of life and from lung, liver, and kidney tissue obtained at autopsy. Evidence of iSNVs was found in only three coding regions (E1A, DNA polymerase, and pVII). Different variant combinations were found in different anatomical compartments. The contribution of intrahost genetic diversity to HAdV-associated disease development and progression warrants investigation.
Open AccessA Pediatric Case of Rapidly Progressing Disseminated Human Adenovirus C1 Infection with Multiorgan Failure and Evidence of Intra-Host Variation
A strain of human adenovirus type C1 was isolated from multiple anatomical compartments in a pediatric patient with late-onset Pompe disease. Over a period of 23 days from the appearance of fever and respiratory symptoms until death, disease progression was rapid with severe disseminated disease and complications that included respiratory distress, liver failure, cardiac dysfunction, and hemophagocytic lymphohistiocytosis. Detected viral DNAemia peaked at log10 9.52 copies/mL on the last hospitalization day. Next-generation whole-genome sequencing with depth > 2700 reads/position identified the virus as closely related to the prototype strain Adenoid 71 isolated in the US in 1953, and to strains circulating worldwide in recent years. Sequence data analysis revealed the presence of intra-host single nucleotide variants (iSNV) at low frequency in the isolates recovered from a nasopharyngeal swab, blood, urine, and stool specimens obtained during the last three days of life and from lung, liver, and kidney tissue obtained at autopsy. Evidence of iSNVs was found in only three coding regions (E1A, DNA polymerase, and pVII). Different variant combinations were found in different anatomical compartments. The contribution of intrahost genetic diversity to HAdV-associated disease development and progression warrants investigation.
- 10 May 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (5) , e70334
Seroprevalence of Strongyloides stercoralis Among Pediatric Solid Organ Transplant Candidates at a Tertiary Pediatric Medical Center in the United States
Background: SOT recipients with prior Strongyloides stercoralis infection risk hyperinfection post‐transplant. Risk‐based screening may miss at‐risk candidates as endemicity expands beyond classic regions. Methods: Retrospective study of SOT candidates < 26 years at Cincinnati Children's Hospital (2018–2024). Universal serology‐based screening was implemented in 2023. Seroprevalence was estimated with exact 95% CIs; seropositive and seronegative patients were compared on demographic and exposure characteristics. Results: 178 patients were screened. Seroprevalence was 3.4% (6/178; 95% CI 1.2%–7.2%), similar across pre‐universal (4.3%) and universal (2.9%) screening periods. Seropositive patients were older (15.7 vs. 8.5 years; p = 0.015) but did not differ on Appalachian exposure, international travel, eosinophilia, or other classical risk factors. Half of seropositive patients lacked any identifiable exposure criterion. All were asymptomatic and treated with two‐dose ivermectin. Conclusions: S. stercoralis seroprevalence was low but clinically significant in this non‐endemic pediatric SOT cohort. Risk‐based screening would have missed a meaningful proportion of seropositive candidates, supporting consideration of universal screening and underscoring the need for broader regional seroprevalence data.
- 10 May 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (5) , e70334
Seroprevalence of Strongyloides stercoralis Among Pediatric Solid Organ Transplant Candidates at a Tertiary Pediatric Medical Center in the United States
Background: SOT recipients with prior Strongyloides stercoralis infection risk hyperinfection post‐transplant. Risk‐based screening may miss at‐risk candidates as endemicity expands beyond classic regions. Methods: Retrospective study of SOT candidates < 26 years at Cincinnati Children's Hospital (2018–2024). Universal serology‐based screening was implemented in 2023. Seroprevalence was estimated with exact 95% CIs; seropositive and seronegative patients were compared on demographic and exposure characteristics. Results: 178 patients were screened. Seroprevalence was 3.4% (6/178; 95% CI 1.2%–7.2%), similar across pre‐universal (4.3%) and universal (2.9%) screening periods. Seropositive patients were older (15.7 vs. 8.5 years; p = 0.015) but did not differ on Appalachian exposure, international travel, eosinophilia, or other classical risk factors. Half of seropositive patients lacked any identifiable exposure criterion. All were asymptomatic and treated with two‐dose ivermectin. Conclusions: S. stercoralis seroprevalence was low but clinically significant in this non‐endemic pediatric SOT cohort. Risk‐based screening would have missed a meaningful proportion of seropositive candidates, supporting consideration of universal screening and underscoring the need for broader regional seroprevalence data.
- Open Access
- 22 February 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70175
Utility of Computed Tomography Surveillance of Asymptomatic Infection in Children and Young Adults Before Allogeneic Hematopoietic Stem Cell Transplant
Asymptomatic infection poses a significant risk for children undergoing hematopoietic stem cell transplantation (HSCT). Pre‐transplant surveillance computed tomography (CT) is commonly used to identify occult infection, though its diagnostic yield remains uncertain. We retrospectively reviewed pre‐HSCT CT examinations from 635 first‐time allogeneic transplant recipients to assess the frequency of occult pulmonary and abdominal infection. Potentially infectious findings were reported in 22% (110/494) of chest CTs but were uncommon in abdomen/pelvis CTs (2%; 7/449). These findings suggest that chest‐only surveillance imaging may be more efficient and could reduce unnecessary radiation and contrast exposure in pediatric HSCT candidates.
- 22 February 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70175
Open AccessUtility of Computed Tomography Surveillance of Asymptomatic Infection in Children and Young Adults Before Allogeneic Hematopoietic Stem Cell Transplant
Asymptomatic infection poses a significant risk for children undergoing hematopoietic stem cell transplantation (HSCT). Pre‐transplant surveillance computed tomography (CT) is commonly used to identify occult infection, though its diagnostic yield remains uncertain. We retrospectively reviewed pre‐HSCT CT examinations from 635 first‐time allogeneic transplant recipients to assess the frequency of occult pulmonary and abdominal infection. Potentially infectious findings were reported in 22% (110/494) of chest CTs but were uncommon in abdomen/pelvis CTs (2%; 7/449). These findings suggest that chest‐only surveillance imaging may be more efficient and could reduce unnecessary radiation and contrast exposure in pediatric HSCT candidates.
- 5 November 2025
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (1)
Epidemiology of Invasive Fungal Disease in Pediatric Heart Transplant Recipients
We describe the epidemiology of invasive fungal disease (IFD) in pediatric heart transplant recipients. Eight patients (4%) suffered IFD. Prolonged central access, delayed chest closure, broad-spectrum antibiotics, and extracorporeal membrane oxygenation (ECMO) were associated with early post-transplant IFD. Delayed chest closure and ECMO were associated with administration of systemic antifungals.
- 5 November 2025
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (1)
Epidemiology of Invasive Fungal Disease in Pediatric Heart Transplant Recipients
We describe the epidemiology of invasive fungal disease (IFD) in pediatric heart transplant recipients. Eight patients (4%) suffered IFD. Prolonged central access, delayed chest closure, broad-spectrum antibiotics, and extracorporeal membrane oxygenation (ECMO) were associated with early post-transplant IFD. Delayed chest closure and ECMO were associated with administration of systemic antifungals.
- 7 May 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (4) , e70088
Child Organ Offer Process ( cOOPS ): Understanding Infectious Risk Assessment and Mitigation Strategies
Introduction: Pediatric Infectious Disease (PID) clinicians involved in solid organ transplantation often assess infection risk and mitigation strategies for donor organ offers. While some guidance is available, real‐life practice patterns have not been previously described. Methods: We surveyed PID clinicians about organ acceptance and associated posttransplantation interventions using 12 fictitious pediatric case scenarios through 3 PID‐specific listservs. Descriptive statistics were employed. Results: 48 (71.6%) of 67 ID respondents were involved in organ offer assessment. Agreement was strong (> 80%) to accept (syphilis, severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2], MRSA, E. coli , TB [liver], rhino/enterovirus) or decline (undifferentiated encephalitis, TB [lung]) organs from these cases, while there was less agreement for cases with risk of coccidioidomycosis, Chagas disease, multi‐drug‐resistant Acinetobacter baumannii , and influenza. Less agreement was present for posttransplant monitoring and antimicrobial administration. Practice varied in testing and treatment for donors with SARS‐CoV‐2 positive test, MRSA bacteremia, and Chagas disease. Conclusions: For many pediatric organ offer scenarios, agreement in donor acceptance was high; however, improved education based on currently available recommendations may enhance organ acceptance decision‐making. The variability in management highlights educational and research opportunities to optimize strategies to limit the impact of donor‐derived infections in pediatric organ recipients.
- 7 May 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (4) , e70088
Child Organ Offer Process ( cOOPS ): Understanding Infectious Risk Assessment and Mitigation Strategies
Introduction: Pediatric Infectious Disease (PID) clinicians involved in solid organ transplantation often assess infection risk and mitigation strategies for donor organ offers. While some guidance is available, real‐life practice patterns have not been previously described. Methods: We surveyed PID clinicians about organ acceptance and associated posttransplantation interventions using 12 fictitious pediatric case scenarios through 3 PID‐specific listservs. Descriptive statistics were employed. Results: 48 (71.6%) of 67 ID respondents were involved in organ offer assessment. Agreement was strong (> 80%) to accept (syphilis, severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2], MRSA, E. coli , TB [liver], rhino/enterovirus) or decline (undifferentiated encephalitis, TB [lung]) organs from these cases, while there was less agreement for cases with risk of coccidioidomycosis, Chagas disease, multi‐drug‐resistant Acinetobacter baumannii , and influenza. Less agreement was present for posttransplant monitoring and antimicrobial administration. Practice varied in testing and treatment for donors with SARS‐CoV‐2 positive test, MRSA bacteremia, and Chagas disease. Conclusions: For many pediatric organ offer scenarios, agreement in donor acceptance was high; however, improved education based on currently available recommendations may enhance organ acceptance decision‐making. The variability in management highlights educational and research opportunities to optimize strategies to limit the impact of donor‐derived infections in pediatric organ recipients.
- 30 April 2025
- Published by Springer Nature
- p. 361-372
Eosinophilic Meningitis
- 5 February 2025
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 14 (3)
Receipt of Fluoroquinolone Prophylaxis is not Associated With Development of Vancomycin-Resistant Enterococcus Colonization During Pediatric Hematopoietic Cell Transplantation
Fluoroquinolones are used to prevent bloodstream infections in pediatric hematopoietic cell transplant (HCT) recipients. We performed a retrospective cohort study in 799 pediatric HCT patients to evaluate the association between fluoroquinolone prophylaxis and VRE colonization. Propensity score analyses were performed. Fluoroquinolone prophylaxis was not associated with VRE colonization.
- 5 February 2025
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 14 (3)
Receipt of Fluoroquinolone Prophylaxis is not Associated With Development of Vancomycin-Resistant Enterococcus Colonization During Pediatric Hematopoietic Cell Transplantation
Fluoroquinolones are used to prevent bloodstream infections in pediatric hematopoietic cell transplant (HCT) recipients. We performed a retrospective cohort study in 799 pediatric HCT patients to evaluate the association between fluoroquinolone prophylaxis and VRE colonization. Propensity score analyses were performed. Fluoroquinolone prophylaxis was not associated with VRE colonization.
- 11 December 2024
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 14 (1)
Clinical Impact of Bronchoalveolar Lavage in Pediatric and Young Adult Patients With Cancer and Suspected Respiratory Infections
Background: Respiratory infections cause a significant amount of morbidity and mortality in pediatric and young adult patients with malignancy. Bronchoscopy with bronchoalveolar lavage (BAL) is frequently utilized in the diagnostic process, but which patients would most benefit is poorly understood. Methods: A retrospective study from 2013 to 2022 examined patients with active malignancy who underwent bronchoscopy with BAL. Positive and negative clinical impacts were assessed by 3 independent reviewers according to predetermined criteria. Mixed-effects logistic regression was performed to identify factors associated with positive and negative clinical impact. Results: In total, 145 bronchoscopies met inclusion criteria with a median patient age of 12 years (interquartile range 5-17). A total of 30.3% of bronchoscopies had a positive clinical impact with 17.2% leading to a new diagnosis, most commonly Pneumocystis jirovecii pneumonia (PJP) (7.6%). Comparatively, 18.6% had a negative clinical impact, most commonly from a procedural complication (13.1%). Trimethoprim-sulfamethoxazole (TMP-SMX) initiation for treatment of suspected PJP prior to BAL (adjusted odds ratio [aOR] 11.20, 95% CI 1.32-95.29) was associated with positive clinical impact. Requirement for ICU-level care (aOR 18.85, 95% CI 3.60-98.69) or oxygen supplementation by nasal cannula prior to BAL (aOR 18.41, 95% CI 4.78-70.95) were associated with negative clinical impact while prior invasive ventilation (aOR 0.09, 95% CI 0.01-0.58) was associated with the absence of negative clinical impact. Conclusions: Patients with potential respiratory infections with high clinical suspicion for PJP who had been started on treatment TMP-SMX prior to BAL benefit most from bronchoscopy with BAL. Patients intubated prior to BAL who were deemed clinically safe for bronchoscopy tolerated the procedure better than those in the ICU not requiring intubation or those requiring supplemental oxygen via nasal cannula.
- 11 December 2024
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 14 (1)
Clinical Impact of Bronchoalveolar Lavage in Pediatric and Young Adult Patients With Cancer and Suspected Respiratory Infections
Background: Respiratory infections cause a significant amount of morbidity and mortality in pediatric and young adult patients with malignancy. Bronchoscopy with bronchoalveolar lavage (BAL) is frequently utilized in the diagnostic process, but which patients would most benefit is poorly understood. Methods: A retrospective study from 2013 to 2022 examined patients with active malignancy who underwent bronchoscopy with BAL. Positive and negative clinical impacts were assessed by 3 independent reviewers according to predetermined criteria. Mixed-effects logistic regression was performed to identify factors associated with positive and negative clinical impact. Results: In total, 145 bronchoscopies met inclusion criteria with a median patient age of 12 years (interquartile range 5-17). A total of 30.3% of bronchoscopies had a positive clinical impact with 17.2% leading to a new diagnosis, most commonly Pneumocystis jirovecii pneumonia (PJP) (7.6%). Comparatively, 18.6% had a negative clinical impact, most commonly from a procedural complication (13.1%). Trimethoprim-sulfamethoxazole (TMP-SMX) initiation for treatment of suspected PJP prior to BAL (adjusted odds ratio [aOR] 11.20, 95% CI 1.32-95.29) was associated with positive clinical impact. Requirement for ICU-level care (aOR 18.85, 95% CI 3.60-98.69) or oxygen supplementation by nasal cannula prior to BAL (aOR 18.41, 95% CI 4.78-70.95) were associated with negative clinical impact while prior invasive ventilation (aOR 0.09, 95% CI 0.01-0.58) was associated with the absence of negative clinical impact. Conclusions: Patients with potential respiratory infections with high clinical suspicion for PJP who had been started on treatment TMP-SMX prior to BAL benefit most from bronchoscopy with BAL. Patients intubated prior to BAL who were deemed clinically safe for bronchoscopy tolerated the procedure better than those in the ICU not requiring intubation or those requiring supplemental oxygen via nasal cannula.